Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?

Journal Article

Myeloid growth factors can reduce the risk of chemotherapy-induced neutropenia (CIN) and thus impact the survival of patients with cancer. Patients should be assessed for risk, taking into consideration patient-related risk factors and chemotherapy regimens. Patients stratified as having at least a 20% risk for CIN should be considered for prophylactic growth factors. The NCCN Guidelines for Myeloid Growth Factors provide category 1 recommendations for the daily use of filgrastim, tbo-filgrastim, and pegfilgrastim. Cancer-related anemia can be treated with erythropoiesis-stimulating agents, red blood cell transfusion, or intravenous iron.

Full Text

Duke Authors

Cited Authors

  • Crawford, J; Rodgers, GM

Published Date

  • May 2014

Published In

Volume / Issue

  • 12 / 5 Suppl

Start / End Page

  • 821 - 824

PubMed ID

  • 24853225

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2014.0198

Language

  • eng